MARKET

DRUG

DRUG

Bright Minds Biosciences Inc
NASDAQ
22.50
-1.61
-6.68%
Opening 13:52 11/10 EST
OPEN
23.77
PREV CLOSE
24.11
HIGH
24.99
LOW
22.13
VOLUME
107.25K
TURNOVER
--
52 WEEK HIGH
123.75
52 WEEK LOW
17.40
MARKET CAP
221.94M
P/E (TTM)
-11.0073
1D
5D
1M
3M
1Y
5Y
1D
Bright Minds Biosciences (DRUG) Shareholder Investigation: Were BMB-101 Preclinical Safety and Data Risks Adequately Disclosed?
TipRanks · 21h ago
Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & Korsinsky
PR Newswire · 1d ago
Weekly Report: what happened at DRUG last week (1102-1106)?
Weekly Report · 1d ago
Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split
NASDAQ · 4d ago
Psychedelic: Compass Pathways beats Q3 loss estimate
TipRanks · 5d ago
Bright Minds Biosciences: Promising Catalysts Despite The FDA Setback
Seeking Alpha · 5d ago
Bright Minds Biosciences: Downgrade To 'Hold' On BMB-101 Setback DEE And Progression Into PWS
Seeking Alpha · 6d ago
DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds Biosciences
PR Newswire · 6d ago
More
About DRUG
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Webull offers Bright Minds Biosciences Inc stock information, including NASDAQ: DRUG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRUG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRUG stock methods without spending real money on the virtual paper trading platform.